23andMe SPAC Presentation Deck slide image

23andMe SPAC Presentation Deck

80% Customers receive a report with a meaningful genetic variant 6,000+ Customers with a tested BRCA1 / BRCA2 variant 12,000+ Customers with an increased risk for Chronic Kidney Disease 7,000+ Customers with Hypercholesterolemia (FH) variants Note: Estimates based on penetrance of variants in 23and Me's Database. Providing Customers With Key, Actionable Insights "Like me, there are many women who have slipped through the cracks of our current medical screening system, either because they don't have a family history of breast or ovarian cancer. Or they do not know that they have Ashkenazi Jewish ancestry. In my case, even though I know I have Ashkenazi ancestry, that wasn't enough to prompt my doctor to consider screening. So there are many women walking around with this risk, who, like me, would have never known of their own risk but for this test from 23andMe." 23andMe customer who discovered she had a BRCA1 mutation 23andMe Confidential and Proprietary Information 7
View entire presentation